Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA panel to review Medtronic's Endeavor stent PMA (pre-market approval) in October:

This article was originally published in Clinica

Executive Summary

An advisory panel from the US FDA is to convene in October in order to review the pre-market approval (PMA) application for Medtronic's Endeavor stent. The agency will announce the date and agenda for the meeting four to six weeks in advance. The PMA application was submitted last November, and was expected to be approved in mid-2007. The Minneapolis, Minnesota-based firm has now altered this expectation; Scott Ward, president of the cardiovascular business at Medtronic, said that approval was anticipated later this calendar year. Analyst Glenn Reicin, however, has described this expectation as an example of "perpetual overoptimism"; there is "no way" the FDA will approve it before 2008, he told the New York Times. The device was CE marked in 2005.

You may also be interested in...

Expanding The Tent: Improving Trial Participation Among Under-Represented Patient Populations

The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.

Wave Of Launches Boosts US Biosimilars Market

A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.

Do Medtechs Know What They Want To Achieve With Digital?

It is the question that continues to exercise the minds of management boards in the medtech industry even as digital health care tools become increasingly ingrained in commercial R&D and operations –  and in patient treatment pathways.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts